Loading
Oragenics Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Telling Fred, was filed 21 Jun 2022.
Oragenics Inc: what insiders have been doing
Oragenics Inc is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). The last twelve months, up to 21 October 2026, brought 1 filing signed by 1 insider.
Only sales appear on the open market, 1 sale in all totalling €169, filed by 1 insider. At €169, the sale published on 15 December 2025 by Telling Fred is the largest of the period.
Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
For context, the typical company on the same exchange (median of 5,454 companies) published 22 filings over the same period, against 1 filing here. Over the whole record (from 2016), the tally stands at 21 purchases and 16 sales.
For comparison within the same sector, see the insider buying recorded at Xenon Pharmaceuticals Inc. and Vivos Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
61
Thresholds
n/a
Buy Volume
€4M
21 ops. · all time
Sell Volume
€2M
16 ops. · all time
Who traded when
BuySaleFred Telling2 sales
Odyssey Health, Inc.2 sales
Alan W. Dunton1 sale
Since the insiders bought
- -82.8%Entry US$540.00 · Close at T+365 US$92.70
- -83.9%Entry US$612.00 · Close at T+365 US$98.70
- -76.8%Entry US$1,008.00 · Close at T+365 US$234.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.44
Analyst consensus
Income statement
RevenueUS$32.4k
EBITDA-US$9.2M-28358% margin
Net income-US$9.8M0.0% margin
Valuation
P/Book0.5x
Beta1.26
Balance sheet & cash
Market capUS$2M
Total debtUS$227.3k
Free Cash Flow-US$9.2M
Debt / Equity1%
Profitability & ownership
ROE-1307.1%
ROA-171.5%
% insiders1.9%
% institutions3.1%
Last declaration on 15 December 2025
Declarations61 total
210 shares@ US$0.94460.1% of flowCommon StockSEC:0001382225-25-000002:0
2,000 shares@ US$4.4629.7% of flowCommon Stock - OGENSEC:0001683168-25-004612:0
5,000 shares@ US$4.2770.3% of flowCommon Stock - OGENSEC:0001683168-25-004526:0
5,000 sharesCommon StockSEC:0001493152-24-049989:0
3,597 shares@ US$0.360.9% of flowCommon StockSEC:0001493152-24-049278:0
66 shares@ US$0.36100.0% of flowCommon StockSEC:0001493152-24-049325:0
3,500 shares@ US$3.56818.0% of flowCommon StockSEC:0001493152-23-043456:0
25,000 shares0Common StockSEC:0001493152-23-027579:0
25,000 shares0Common StockSEC:0001493152-23-027582:0
25,000 shares0Common StockSEC:0001493152-23-027577:0
15,000 shares0Common StockSEC:0001493152-23-027578:0
25,000 shares0Common StockSEC:0001493152-23-027581:0
25,000 shares0Common StockSEC:0001493152-23-027580:0
36,648 shares@ US$0.1062.7% of flowCommon StockSEC:0001493152-23-000130:0
25,000 shares@ US$0.1753.0% of flowCommon StockSEC:0001493152-22-035732:0
4,503 shares@ US$0.1750.5% of flowCommon StockSEC:0001493152-22-035570:0
48,795 shares@ US$0.1976.7% of flowCommon StockSEC:0001493152-22-035184:0
13,036 shares@ US$0.201.8% of flowCommon StockSEC:0001493152-22-035043:0
200,000 shares@ US$0.192327.2% of flowCommon StockSEC:0001493152-22-034167:0
10,084 shares@ US$0.2860.10% mcap1.9% of flowCommon StockSEC:0001493152-22-017293:0
Canonical exit: 15 Sept 2022 (T+90)
3,500 shares@ US$0.28690.7% of flowCommon StockSEC:0001493152-22-015040:0
Canonical exit: 21 Aug 2022 (T+90)
65,718 shares@ US$0.283612.4% of flowCommon StockSEC:0001493152-22-014790:0
Canonical exit: 18 Aug 2022 (T+90)
15,303 shares@ US$0.2612.7% of flowCommon StockSEC:0001493152-22-014605:0
Canonical exit: 16 Aug 2022 (T+90)
124,785 shares@ US$0.362928.7% of flowCommon StockSEC:0001493152-22-008799:0
Canonical exit: 28 Jun 2022 (T+90)
20,000 shares@ US$0.3461100.0% of flowCommon StockSEC:0001493152-22-008135:0
Canonical exit: 27 Jun 2022 (T+90)
25 of 61 declarations
About Oragenics Inc
Oragenics, Inc. (ticker: OGEN) is a United States-based biopharmaceutical company listed on NYSE American, placing it within the broader NYSE/NASDAQ small-cap healthcare universe. The company is headquartered in Sarasota, Florida, and was incorporated in November 1996. Over time, Oragenics has shifted its strategy toward intranasal therapies aimed at neurological conditions, moving away from a broader legacy portfolio and into a more focused development-stage model. That strategic narrowing makes the equity story easier to understand, but also increases dependence on a small number of clinical and regulatory milestones.
Today, the company’s main asset is ONP-002, a first-in-class intranasal neurosteroid being developed for mild traumatic brain injury, commonly referred to as concussion. Oragenics positions the program as a potential treatment for an area of high unmet medical need, where there are few approved options and where rapid delivery to the brain may matter clinically. The formulation is designed for nasal administration using a proprietary intranasal device, which management believes could support efficient delivery to the central nervous system. According to recent filings, ONP-002 is advancing through Phase IIa clinical trials in Australia, with U.S. Phase IIb studies planned afterward. This makes Oragenics a classic development-stage biotech: the long-term value proposition is tied to clinical data rather than current revenue generation.
Read moreShow less
The company’s history reflects several strategic pivots. In earlier years, Oragenics explored other research areas, including infectious disease-related programs, nasal vaccine concepts, and antibacterial compounds. Those legacy initiatives are no longer the primary investment focus. Recent disclosures indicate that the company has concentrated resources on ONP-002, with spending directed toward regulatory preparation, manufacturing readiness, and consulting support. Oragenics has also indicated that its intranasal delivery platform may have broader applications across multiple neurological conditions, suggesting optionality beyond the lead asset. In addition, management has referenced strategic business-development opportunities, including partnerships, licensing, and potential acquisitions in CNS-related areas.
From a competitive standpoint, Oragenics operates in a crowded and scientifically demanding niche. Its differentiation depends on whether the intranasal route can deliver meaningful clinical advantages in concussion and related brain-injury settings, and whether trial results can support further development, partnering, or eventual commercialization. The company is small, capital constrained, and highly exposed to financing needs, dilution risk, and execution risk. It does not yet have the scale of a commercial specialty pharma company, so investors should view it as a high-risk, high-optional biotech story rather than a mature operating business.
Recent company updates have centered on clinical progress, financing activity, and strategic exploration of external opportunities in brain health and CNS recovery. For investors looking at U.S.-listed healthcare microcaps, Oragenics is a speculative NASDAQ/NYSE-type biotech profile listed on NYSE American, with upside tied to clinical success and downside constrained by limited operating scale and continuing funding requirements.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
